Eudaimonia Partners’s Pfizer PFE Stock Holding History

Eudaimonia Partners’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$355K	Sell	12,809 -1,641	-11%	-$45.5K	0.08%	181
2023 Q4	$416K	Sell	14,450 -12,072	-46%	-$365K	0.11%	156
2023 Q3	$880K	Sell	26,522 -1,067	-4%	-$37.7K	0.21%	106
2023 Q2	$1.01M	Sell	27,589 -557	-2%	-$21.7K	0.23%	109
2023 Q1	$1.15M	Sell	28,146 -1,715	-6%	-$74.1K	0.28%	96
2022 Q4	$1.53M	Sell	29,861 -3,227	-10%	-$155K	0.38%	67
2022 Q3	$1.45M	Sell	33,088 -44,443	-57%	-$2.16M	0.38%	66
2022 Q2	$4.07M	Buy	77,531 +897	+1%	+$45.7K	0.75%	28
2022 Q1	$3.97M	Buy	+76,634	New	+$3.98M	0.67%	31
2021 Q3	$3.06M	Sell	71,068 -2,165	-3%	-$95.9K	0.55%	42
2021 Q2	$2.87M	Buy	73,233 +6,224	+9%	+$242K	0.54%	48
2021 Q1	$2.43M	Buy	67,009 +728	+1%	+$25.8K	0.5%	48
2020 Q4	$2.44M	Sell	66,281 -3,861	-6%	-$142K	0.55%	47
2020 Q3	$2.44M	Buy	70,142 +573	+0.8%	+$20.1K	0.63%	41
2020 Q2	$2.16M	Sell	69,569 -2,906	-4%	-$98.7K	0.82%	28
2020 Q1	$2.24M	Buy	72,475 +4,500	+7%	+$153K	0.99%	20
2019 Q4	$2.53M	Buy	+67,975	New	+$2.42M	1%	17

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Eudaimonia Partners's PFE Position: Q1 2024 in Review

Eudaimonia Partners reduced its Pfizer (PFE) stake by 11% in Q1 2024, selling an estimated $45.5K and leaving 12,809 shares worth $355K. The position accounts for 0.08% of the portfolio, ranked #181.

Eudaimonia Partners first reported a position in PFE in Q4 2019 and has held it in 17 quarters since. The position peaked at $4.07M in Q2 2022. 2,874 funds tracked by Wall St. Rank hold PFE as of Q1 2024.

Eudaimonia Partners held 12,809 shares of Pfizer worth $355K as of Q1 2024.
Eudaimonia Partners sold 1,641 Pfizer shares in Q1 2024, an estimated $45.5K.
Pfizer made up 0.08% of Eudaimonia Partners's portfolio in Q1 2024, its #181 holding.
Eudaimonia Partners first reported a position in Pfizer in Q4 2019 and has held it in 17 quarters since.
Eudaimonia Partners's Pfizer position peaked at $4.07M in Q2 2022.
2,874 funds tracked by Wall St. Rank held Pfizer as of Q1 2024.

Based on Eudaimonia Partners's 13F filing for Q1 2024, filed 25 Apr 2024.